# PENELOPE-B (NCT01864746)

> A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01864746
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: GBG Forschungs GmbH
- Conditions: Breast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor; CPS-EG Score
- Interventions: Palbociclib PD-0332991; Placebo
- Enrollment: 1250
- Primary outcome: Invasive Disease Free Survival (iDFS) for Palbociclib vs. Placebo in Patients With High CPS-EG Score After Neoadjuvant Chemotherapy Receiving Standard Adjuvant Endocrine Therapy for HR-positive/HER2-normal Primary Breast Cancer.

## Commentary we found

- YouTube: 33
- Podcasts: 32
- X threads: 15
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=penelope-b-nct01864746

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01864746", "email": "<work email>"}; the inbox owner confirms by the emailed link.